Getinge elevates automated endoscope reprocessing with Aquadis Endo 110

Today, Getinge announced the launch of Aquadis Endo 110, a next-generation automated endoscope reprocessor designed to increase processing capacity, simplify workflows and enhance safety for both patients and healthcare professionals. Building on decades of expertise in infection control and sterile reprocessing, Aquadis Endo 110 sets a new benchmark for fast, reliable cleaning and high-level disinfection of flexible endoscopes, helping reduce the risk of healthcare‑associated infections. As endoscopy procedure volumes continue to rise, endoscopy departments are facing increased

Getinge Launches Vasoview Hemopro 3, Advancing Endoscopic Vessel Harvesting

Getinge today announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. Designed for clinicians, by clinicians, the system represents the latest evolution of Getinge’s EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures. Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a

Getinge’s subsidiary Maquet Cardiovascular receives adverse jury trial verdict in patent infringement dispute with Abiomed in the U.S.

Getinge today announces that a jury in the United States District Court for the District of Massachusetts has delivered a verdict in favor of Abiomed Inc (“Abiomed”) in a patent dispute between Getinge’s subsidiary Maquet Cardiovascular LLC (“Maquet”) and Abiomed. The jury found that Abiomed has not infringed any Maquet patents relating to intravascular heart pump technology.The patent infringement dispute concerned allegations of infringement in patents held by Maquet relating to intravascular heart pump technology used in cardiovascular care. The technology used in Abiomeds’ Impella

Getinge boosts GSS67N sterilizer throughput with expanded validated load capacity at HSPA 2026

Getinge today unveiled an expansion of its GSS67N steam sterilizer platform at the HSPA 2026 Annual Conference. The updated platform delivers up to 24 trays and 600 lbs of FDA-cleared validated load within the same installed footprint, enabling sterile reprocessing departments to increase output without expanding space, chamber size, or infrastructure. Across the GSS67N family, validated capacity includes: · GSS67N10: 12 trays / 300 lbs · GSS67N13: 16 trays / 400 lbs · GSS67N17: 24 trays / 600 lbs "Peak surgical days test every part of the sterile processing

Resolutions at Getinge’s Annual General Meeting April 21, 2026

Getinge AB (publ)’s Annual General Meeting (“AGM”) was held on April 21, 2026 in Kongresshallen, Hotel Tylösand, Halmstad, Sweden. At the AGM, the following was resolved.Adoption of the Income Statement and the Balance Sheet The AGM adopted the Income Statement and the Balance Sheet as well as the Consolidated Income Statement and the Consolidated Balance Sheet for the financial year 2025. Dividend In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.75 per share. Thursday April 23, 2026 was determined as record date

Getinge Interim Report January-March 2026: Organic growth, strong cash flow and regulatory milestone

“We succeeded in surpassing last year’s record-breaking first quarter with organic growth in both net sales and order intake,” says Mattias Perjos, President & CEO at Getinge. The medtech company’s net sales increased organically by 0,8% while the order intake rose by 3,9% organically.Getinge reports a new record-breaking first quarter despite a decline for Acute Care Therapies, primarily in ventilators, where the medtech company captured shares last year in connection with market consolidation. Consumables for life-supporting ECLS therapy, however, continued to show stable growth from a

Getinge acquires Pennamed to strengthen endoscopy offering in the UK

Getinge today announces the acquisition of Pennamed, a UK-based distributor of endoscopic consumables serving National Health Service (NHS) and independent healthcare providers.The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology. Together, Getinge and Pennamed will support endoscopy teams across the UK Healthcare system with a broader and more

Getinge invites fund managers, analysts, and media to Q1 Report 2026 conference call

Getinge will issue its Q1 Report 2026 on April 21, 2026, at 12.00 p.m. CEST, followed by a conference call at 13:00 p.m. CEST, hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO.Fund managers, analysts and media are invited to participate in the conference call. To participate via teleconference, please register via this link . After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference. During the

Getinge publishes Annual Report for 2025

Today, Getinge publishes its Annual Report for 2025, including the Sustainability statement. The year was marked by geopolitical friction and significant cost impacts from tariffs and currency movements, while the company delivered strong underlying profitability, continued regulatory progress, and an ambitious innovation agenda.Getinge’s 2025 Annual Report summarizes the year’s performance, both financially and in sustainability, and provides an overview of the company’s strategy, targets, and governance. The medtech company’s net sales in 2025 amounted to SEK 35 billion, with organic

Getinge Advances ECLS Technology with Cardiohelp II – The Next Evolution in Extracorporeal Life Support

Getinge today announced the receipt of CE mark for Cardiohelp II, the next evolution of its extracorporeal life support (ECLS) platform. Building on the legacy of Cardiohelp-i - widely recognized within acute care for shaping modern extracorporeal membrane oxygenation (ECMO) transport and extracorporeal life support practice - Cardiohelp II represents the next step forward in intelligent, connected and clinically advanced ECLS. As a global leader in cardiopulmonary technologies, Getinge has played a defining role in the development and broader adoption of modern ECLS practice.

Getinge’s iCast covered stent system expands U.S. offering with additional sizes

Getinge has received U.S. FDA Premarket Approval (PMA) for additional sizes of its iCast covered stent system, expanding treatment options for patients with occlusive disease. The approval includes a new 10 mm diameter by 59 mm length, new 32 mm lengths, and new 12 mm large diameter options. These newly approved sizes enable physicians to treat a broader range of vessel and lesion diameters and lengths, increasing procedural flexibility and expanding access to the iCast covered stent system for more patients across the U.S. ”We are excited to bring this important portfolio

NOTICE OF ANNUAL GENERAL MEETING IN GETINGE AB (PUBL)

The shareholders of Getinge AB (publ), corporate ID No. 556408-5032, (“Getinge”) are hereby invited to attend the Annual General Meeting (the “AGM”) on Tuesday, April 21, 2026 at 3.00 p.m. CEST, in Kongresshallen, Hotel Tylösand, Halmstad, Sweden. Entrance registration starts at 2.00 p.m. CEST. A lighter snack will be served after the AGM. The Board of Directors of Getinge has decided that the shareholders shall be able to exercise their voting right at the AGM by postal voting in accordance with the regulations in Getinge’s Articles of Association, as further described below.RIGHT TO

Getinge Q4 and Full-Year Report 2025: Organic growth and solid cash flow to end the year

“We succeeded in growing organically, delivering a record-breaking fourth quarter and organic growth at the upper end of our forecast, 4.9% for the full year,” says Mattias Perjos, President & CEO at Getinge.Higher demand for consumables for ECLS-therapy in the quarter and in Acute Care Therapies contributed to Getinge’s performance. Sales were also strong in Transplant Care and ventilators. Surgical Workflows continued to strengthen its market-leading position in operating tables and enters 2026 with robust order bookings. In general, sales are more volatile between quarters for Life

Getinge invites fund managers, analysts, and media to Year-End Report 2025 conference call

Getinge will issue its Year-End Report 2025 on January 27, 2026, at 08.00 a.m. CET, followed by a conference call at 10.00 a.m. CET, hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO.Fund managers, analysts and media are invited to participate in the conference call. To participate via teleconference, please register via this link . After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference. During the

Getinge transforms sterile reprocessing with Automatiq - a full range of logistic automation modules

Getinge is unveiling Automatiq, a new family of next generation automated solutions designed to help Central Sterile Supply Departments (CSSDs) achieve safer, more consistent and less labor-intensive sterile reprocessing. Automatiq seamlessly combines smart robotics, intelligent conveyor systems and advanced software to optimize sterile reprocessing and enhance workflow efficiency at every step. CSSDs play a vital role in infection prevention and represent one of the most precise and physically demanding processes in the hospital. During traditional manual processes, CSSD

Camilla Sylvest is proposed for Getinge AB’s Board of Directors

The Nomination Committee of Getinge AB (publ) has decided to propose to the Annual General Meeting 2026 that the Meeting elects Camilla Sylvest as a new member of the Board of Directors. The Nomination Committee also informs that the current Board member Malin Persson, who has served since 2014, has announced that she will not be available for re-election in 2026.Camilla Sylvest has more than 28 years of experience at Novo Nordisk A/S, most recently serving eight years as Executive Vice President, Commercial Strategy and Corporate Affairs, and as a member of the executive management team.

Getinge and SteriPro International Inc. announce strategic partnership for sterile processing optimization

Today, Getinge and SteriPro International Inc. announced a new strategic partnership that reinforces safer workflows and a scalable model for the future of surgical services within Sterile Processing departments across North America. The unique partnership brings together two complementary strengths: Getinge’s proven leadership in sterile processing equipment, automation, and digital workflow solutions, and SteriPro’s deep expertise in off-site reprocessing operations. Together, Getinge and SteriPro look to raise quality, increase transparency, and steer meaningful cost

Getinge introduces new version of Solsus 66 to meet CSSD efficiency needs

Getinge introduces a new version of its trusted Solsus 66 Steam Sterilizer – originally launched in 2020 – designed to meet the evolving needs of Central Sterile Supply Departments (CSSDs). Sterile reprocessing is essential to safe and efficient healthcare. Hospitals face increasing pressure to deliver high-quality care while managing costs and space. Getinge´s Solsus 66 helps CSSDs meet these demands. Built on robust technology with over 20 years of heritage, it has become a reliable partner in sterile reprocessing. The new version retains its proven performance while introducing

Utility-efficient washer-disinfector Aquadis 44 helps hospitals reduce costs and meet environmental targets

Getinge today launches Aquadis 44, its latest washer-disinfector designed to minimize utility use and lower operating costs. This innovative model helps healthcare providers decrease their environmental impact while ensuring reliable performance and ease of use. Hospitals are under growing pressure to reduce their environmental footprint without compromising the quality of care. Getinge’s latest washer-disinfector Aquadis 44 responds to this challenge with a combination of low total cost of ownership, improved ergonomics and patent-pending innovations – including adaptive water

Getinge boosts cleanroom efficiency with modern interface for cGMP washers and sterilizers

Getinge is advancing efficient cleanroom operations in the biopharma industry by integrating a new open and flexible visualization system in its new generation cGMP washers and sterilizers. SIMATIC WinCC Unified, Siemens’ latest open interface, offers a unified solution for effortless integration of both Getinge washers and sterilizers - delivering efficiency and ease of use. “Meeting the digitalization challenges in the pharmaceutical industry is one of our priorities. The integration of one common easy-to-use interface for controlling and monitoring all Getinge washers and

Getinge Interim Report July-September 2025: High organic sales growth and stronger margins despite geopolitical headwinds

“We demonstrated strength in the third quarter with significant organic growth, improved profitability and cash flow despite impacts from tariffs and negative currency effects," says Mattias Perjos, President & CEO, Getinge. The medtech company’s net sales increased organically by 9,5% while order intake rose by 4,7% organically.Acute Care Therapies continued to meet the higher demand for ventilators, in the wake of an ongoing market consolidation. Order intake and sales of ECLS consumables were also significant. Both Life Science and Surgical Workflows set sales records for the third

Getinge’s Advanta V12 receives CE Mark for major bridging indications

Getinge’s Advanta™ V12 is now approved for major bridging indications, marking a milestone in complex aortic aneurysm treatment. Today, Getinge announces that its Advanta™ V12 Covered Stent System has received CE Mark approval under the European Union Medical Device Regulation (EU MDR) for use as a bridging stent in fenestrated endovascular aneurysm repair (FEVAR), branched endovascular aneurysm repair (BEVAR), and iliac branch device (IBD) aneurysmal repair. This landmark approval offers physicians a trusted, on-label solution backed by over two decades of clinical use.Advanta

Getinge invites fund managers, analysts, and media to Q3 Report 2025 conference call

Getinge will issue its Q3 Report 2025 on October 21, 2025, at 08.00 a.m. CEST, followed by a conference call at 10.00 a.m. CEST, hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO.Fund managers, analysts and media are invited to participate in the conference call. To participate via teleconference, please register via this link . After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference. During the

Getinge and Philips introduce integrated anesthesia workstation

Getinge and Philips have joined forces to offer hospitals an integrated anesthesia workstation for the operating room (OR). The new solution unites precise anesthesia delivery and state-of-the-art patient monitoring. The integrated anesthesia workstation combines two leading anesthesia care and monitoring solutions: Getinge’s Flow Family Anesthesia Machines and Philips IntelliVue Patient Monitoring technology. “This partnership represents a shared commitment to improving OR efficiency and patient care, and we see great value in collaborating with Philips,” says Juergen Kelch,